These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

406 related items for PubMed ID: 27122198

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. [New developments in anaemia treatment - erythropoietin versus prolyl hydroxylase inhibitors?].
    Ryšavá R.
    Vnitr Lek; 2022; 68(7):438-443. PubMed ID: 36402568
    [Abstract] [Full Text] [Related]

  • 23. Activin receptor ligand traps in chronic kidney disease.
    Jelkmann W.
    Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):351-357. PubMed ID: 29847322
    [Abstract] [Full Text] [Related]

  • 24. Chronic kidney disease-associated anemia: new remedies.
    Del Vecchio L, Cavalli A, Tucci B, Locatelli F.
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1030-8. PubMed ID: 20730698
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Erythropoietic stimulating agents.
    Testa U.
    Expert Opin Emerg Drugs; 2010 Mar; 15(1):119-38. PubMed ID: 20158404
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Are there advantages of daprodustat over erythropoiesis-stimulating agents (ESAs) in treating anemia associated with chronic kidney disease (CKD)?
    Doggrell SA.
    Expert Opin Pharmacother; 2022 May; 23(7):769-773. PubMed ID: 35380500
    [Abstract] [Full Text] [Related]

  • 30. Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies.
    Del Vecchio L, Locatelli F.
    Expert Rev Hematol; 2014 Aug; 7(4):495-506. PubMed ID: 25025373
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia.
    Arantes LH, Crawford J, Gascon P, Latymer M, Launay-Vacher V, Rolland C, Scotte F, Wish J.
    Crit Rev Oncol Hematol; 2018 Sep; 129():79-90. PubMed ID: 30097240
    [Abstract] [Full Text] [Related]

  • 34. Treatment of Anemia Associated with Chronic Kidney Disease: Plea for Considering Physiological Erythropoiesis.
    Kuragano T.
    Int J Mol Sci; 2024 Jul 03; 25(13):. PubMed ID: 39000429
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia in heart failure patients: A protocol for systematic review and meta-analysis.
    Fukuta H, Hagiwara H, Kamiya T.
    PLoS One; 2022 Jul 03; 17(9):e0275311. PubMed ID: 36170343
    [Abstract] [Full Text] [Related]

  • 37. Hypoxia-Inducible Factor-Prolyl Hydroxyl Domain Inhibitors: From Theoretical Superiority to Clinical Noninferiority Compared with Current ESAs?
    Locatelli F, Del Vecchio L.
    J Am Soc Nephrol; 2022 Nov 03; 33(11):1966-1979. PubMed ID: 36041790
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. New expectations in the treatment of anemia in chronic kidney disease.
    López-Gómez JM, Abad S, Vega A.
    Nefrologia; 2016 Nov 03; 36(3):232-6. PubMed ID: 27137103
    [Abstract] [Full Text] [Related]

  • 40. An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease.
    Kurata Y, Tanaka T, Nangaku M.
    Expert Opin Pharmacother; 2022 Jan 03; 23(1):19-28. PubMed ID: 34686069
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.